Aspire Biopharma Holdings, Inc, a developer of a multi-faceted patent-pending drug delivery technology, announced initiation of its phase 1 single-centre clinical study of its lead therapeutic ...

Experts say stopping aspirin use based solely on age could be harmful and emphasize individualized decisions made by doctors who understand each patient’s risks and benefits. They also stress the ...

HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / April 9, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery ...

Forward-looking statements may generally be identified by the use of words such as 'estimate,' 'projects ... with control healthy subjects given 162.5 mg oral aspirin (approximately two 81 mg aspirin ...

Aspire intends to request "fast track" approval on FDA application for its high-dose aspirin product HUMACAO ... 5 mg oral aspirin (approximately two 81 mg aspirin tablets).

Phase 1 Study Design The objectives of this Phase 1 single dose clinical study are to evaluate the safety, pharmacokinetics and pharmacodynamics of Aspire's sublingual aspirin powder when ...

AUSTIN, Texas — Texas lawmakers are considering several bills aimed at improving access to mental health and substance use treatment — including for adolescents. On Wednesday, the Texas House ...

Trial designed to evaluate safety, pharmacokinetics and pharmacodynamics, of Aspire's sublingual aspirin product Aspire anticipates releasing initial clinical data from trial at the end of the second ...

HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / April 9, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug ...